Impact of Surgical Timing on Outcome in Papillary Thyroid Cancer Patients in Saudi Arabia
Abstract
1. Introduction
2. Methods
2.1. Study Design and Setting
2.2. Study Population
- Adult patients (≥18 years) with PTC.
- Patients who underwent thyroid surgery as primary treatment.
- Availability of preoperative FNA results and final histopathological evaluation.
- Non-papillary thyroid cancers or other thyroid disorders.
- Papillary thyroid microcarcinoma (≤1 cm), due to its typically indolent behavior and low risk of aggressive histopathological features.
2.3. Data Collection
2.4. Study Variables and Outcome Measures
- ▪
- Age (years)
- ▪
- Sex (male/female)
- ▪
- Body mass index (BMI, kg/m2): calculated as weight (kg) divided by height squared (m2). BMI was categorized according to World Health Organization guidelines:
- Underweight: <18.5
- Normal weight: 18.5–24.9
- Overweight: 25.0–29.9
- Obesity class I: 30.0–34.9
- Obesity class II: 35.0–39.9
- Obesity class III: ≥40.0
- ▪
- Thyroid function: categorized based on preoperative laboratory results:
- Euthyroid: normal TSH and free T4
- Hypothyroid: elevated TSH and/or low free T4
- Hyperthyroid: suppressed TSH and/or elevated free T4
- ▪
- FNA dates and results
- ▪
- Time and type of surgery
2.5. Data Analysis
2.6. Ethical Considerations
3. Results
“A total of 350 papillary thyroid carcinoma cases met the inclusion criteria and were analyzed.”
4. Discussion
4.1. Limitations
4.2. Future Directions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Prete, A.; Borges de Souza, P.; Censi, S.; Muzza, M.; Nucci, N.; Sponziello, M. Update on Fundamental Mechanisms of Thyroid Cancer. Front. Endocrinol. 2020, 11, 102. [Google Scholar] [CrossRef] [PubMed]
- Miranda-Filho, A.; Lortet-Tieulent, J.; Bray, F.; Cao, B.; Franceschi, S.; Vaccarella, S.; Dal Maso, L. Thyroid Cancer Incidence Trends by Histology in 25 Countries: A Population-Based Study. Lancet Diabetes Endocrinol. 2021, 9, 225–234. [Google Scholar] [CrossRef] [PubMed]
- Flemban, A.F.; Kabrah, S.; Alahmadi, H.; Alqurashi, R.K.; Turaes, A.S.; Almaghrabi, R.; Al Harbi, S.; Khogeer, A.A. Patterns of Thyroid Cancer Mortality and Incidence in Saudi Arabia: A 30-Year Study. Diagnostics 2022, 12, 2716. [Google Scholar] [CrossRef] [PubMed]
- Alqahtani, W.S.; Almufareh, N.A.; Domiaty, D.M.; Albasher, G.; Alduwish, M.A.; Alkhalaf, H.; Almuzzaini, B.; Al-Marshidy, S.S.; Alfraihi, R.; Elasbali, A.M.; et al. Epidemiology of Cancer in Saudi Arabia Through 2010–2019: A Systematic Review with Constrained Meta-Analysis. AIMS Public Health 2020, 7, 679–696. [Google Scholar] [CrossRef] [PubMed]
- Jozaghi, Y.; Zafereo, M.E.; Perrier, N.D.; Wang, J.R.; Grubbs, E.; Gross, N.D.; Fisher, S.; Sturgis, E.M.; Goepfert, R.P.; Lai, S.Y.; et al. Endocrine Surgery in the COVID-19 Pandemic: Surgical Triage Guidelines. Head Neck 2020, 42, 1325–1328. [Google Scholar] [CrossRef] [PubMed]
- Baud, G.; Brunaud, L.; Lifante, J.C.; Tresallet, C.; Sebag, F.; Bizard, J.P.; Mathonnet, M.; Menegaux, F.; Caiazzo, R.; Mirallié, E.; et al. Endocrine Surgery During and After the COVID-19 Epidemic: Expert Guidelines from AFCE. J. Visc. Surg. 2020, 157, S43–S49. [Google Scholar] [CrossRef] [PubMed]
- Jeon, M.J.; Kim, W.G.; Kwon, H.; Kim, M.; Park, S.; Oh, H.S.; Han, M.; Sung, T.Y.; Chung, K.W.; Hong, S.J.; et al. Clinical Outcomes After Delayed Thyroid Surgery in Patients with Papillary Thyroid Microcarcinoma. Eur. J. Endocrinol. 2017, 177, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Zhou, H.; Wu, J.; Shi, L.; Wang, Y.; Liu, B. Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-Risk Papillary Thyroid Cancer. J. Clin. Endocrinol. Metab. 2022, 107, 3389–3397. [Google Scholar] [CrossRef] [PubMed]
- Fligor, S.C.; Lopez, B.; Uppal, N.; Lubitz, C.C.; James, B.C. Time to Surgery and Thyroid Cancer Survival in the United States. Ann. Surg. Oncol. 2021, 28, 3556–3565. [Google Scholar] [CrossRef] [PubMed]
- Chaves, N.; Broekhuis, J.M.; Fligor, S.C.; Collins, R.A.; Modest, A.M.; Kaul, S.; James, B.C. Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis. J. Clin. Endocrinol. Metab. 2023, 108, 2589–2596. [Google Scholar] [CrossRef] [PubMed]
- Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef] [PubMed]
- Momesso, D.P.; Tuttle, R.M. Update on Differentiated Thyroid Cancer Staging. Endocrinol. Metab. Clin. N. Am. 2014, 43, 401–421. [Google Scholar] [CrossRef] [PubMed]
- Konturek, A.; Barczyński, M.; Stopa, M.; Nowak, W. Trends in Prevalence of Thyroid Cancer Over Three Decades: A Retrospective Cohort Study of 17,526 Surgical Patients. World J. Surg. 2016, 40, 538–544. [Google Scholar] [CrossRef] [PubMed]
- Hajeer, M.H.; Awad, H.A.; Abdullah, N.I.; Almuhaisen, G.H.; Abudalu, L.E. The Rising Trend in Papillary Thyroid Carcinoma: True Increase or Overdiagnosis? Saudi Med. J. 2018, 39, 147–153. [Google Scholar] [CrossRef] [PubMed]
- Hussain, F.; Iqbal, S.; Mehmood, A.; Bazarbashi, S.; ElHassan, T.; Chaudhri, N. Incidence of Thyroid Cancer in the Kingdom of Saudi Arabia, 2000–2010. Hematol. Oncol. Stem Cell Ther. 2013, 6, 58–64. [Google Scholar] [CrossRef] [PubMed]
- O’Neill, R.J.; Abd Elwahab, S.; Kerin, M.J.; Lowery, A.J. Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. World J. Surg. 2021, 45, 2805–2815. [Google Scholar] [CrossRef] [PubMed]
| Characteristics | N | % |
|---|---|---|
| Gender | ||
| Male | 82 | 23.4% |
| Female | 268 | 76.6% |
| Age categories | ||
| <55 years | 304 | 86.9% |
| ≥55 years | 46 | 13.1% |
| Mean ± SD | 40.7 ± 13.4 | |
| BMI categories | ||
| Within normal | 76 | 21.7% |
| Overweight | 108 | 30.9% |
| Obese | 94 | 26.9% |
| Morbid obesity | 72 | 20.5% |
| Thyroid function | ||
| Euthyroid | 292 | 83.4% |
| Hypothyroid | 22 | 6.3% |
| Hyperthyroid | 36 | 10.3% |
| Duration between diagnosis and surgery | ||
| <6 months | 262 | 74.9% |
| ≥6 months | 88 | 25.1% |
| Type of surgery | ||
| TT | 211 | 60.3% |
| TT and CND | 33 | 9.4% |
| TT and UND | 36 | 10.3% |
| TT and BND | 17 | 4.9% |
| Comp | 36 | 10.3% |
| Comp and CND | 2 | 0.6% |
| Comp and UND | 1 | 0.3% |
| Comp and BND | 6 | 1.7% |
| Right hemithyroidectomy | 8 | 2.3% |
| Left hemithyroidectomy | 8 | 2.3% |
| FNA Results | N | % |
|---|---|---|
| PTC | 130 | 37.1% |
| Suspecouic for PTC | 63 | 18.0% |
| Atypia of Undetermined Significance (AUS) | 61 | 17.4% |
| Benign | 58 | 16.6% |
| Follicular Neoplasm | 28 | 8.0% |
| Not diagnostic | 10 | 2.9% |
| Histopathology of the Tumor | N | % |
|---|---|---|
| Pathology type | ||
| PTC Classical | 193 | 55.1% |
| PTC follicular variant | 96 | 27.4% |
| PTC Classical and PTC follicular variant | 33 | 8.9 |
| PTC Classical and PTC oncocytic variant | 9 | 2.7 |
| PTC Classical and other PTC variants | 8 | 2.3 |
| PTC oncocytic variant | 5 | 1.4 |
| Other PTC variants (Insular, Tall cell, Columnar, diffuse sclerosing … etc.) | 4 | 1.1 |
| PTC follicular variants and other PTC variants | 4 | 1.1 |
| Tumor related features | ||
| Thyroiditis | 161 | 46.6% |
| Goitrous | 139 | 39.7% |
| ETE (Extrathyroidal Extension) | 116 | 33.1% |
| ECE (Extracapsular Extension) | 129 | 36.9% |
| LN (Lymph Node Involvement) | 120 | 34.3% |
| Neural invasion | 3 | 0.9% |
| Lymphovascular invasion | 70 | 20.0% |
| Margin (n = 334) | ||
| Negative | 167 | 50.0% |
| Close | 100 | 29.9% |
| Positive | 67 | 20.1% |
| Multifocality (339) | ||
| Single focus | 169 | 49.9% |
| Multifocal | 170 | 50.1% |
| Size of the tumor | ||
| <2 cm | 149 | 42.6% |
| 2–4 cm | 131 | 37.4% |
| ≥4 cm | 70 | 20.0% |
| Characteristics | Duration | p * | |
|---|---|---|---|
| <6 Months | ≥6 Months | ||
| N (%) | N (%) | ||
| Thyroiditis | |||
| Positive | 123 (76.4) | 38 (23.6) | 0.564 |
| Negative | 120 (73.6) | 43 (26.4) | |
| Goitrous | |||
| Positive | 97 (69.8) | 42 (30.2) | 0.062 |
| Negative | 162 (78.6) | 44 (21.4) | |
| ETE | |||
| Positive | 92 (79.3) | 24 (20.7) | 0.149 |
| Negative | 164 (73.5) | 59 (26.5) | |
| LN | |||
| Positive | 101 (84.2) | 19 (15.8) | 0.004 ** |
| Negative | 161 (70.3) | 68 (29.7) | |
| ECE | |||
| Positive | 101 (78.3) | 28 (21.7) | 0.589 |
| Negative | 82 (81.2) | 19 (18.8) | |
| Lymphovascular invasion | |||
| Positive | 57 (81.5) | 13 (18.6) | 0.265 |
| Negative | 177 (75.0) | 59 (25.0) | |
| Neural invasion | |||
| Positive | 2 (66.7) | 1 (33.3) | 0.507 |
| Negative | 78 (79.6) | 20 (20.4) | |
| Thyroid function | |||
| Euthyroid | 218 (74.7) | 74 (25.3) | |
| Hypothyroid | 15 (68.2) | 7 (31.8) | 0.563 |
| Hyperthyroid | 29 (80.6) | 7 (19.4) | |
| Multifocality | |||
| Single focus | 124 (73.4) | 45 (26.6) | 0.511 |
| Multifocal | 130 (76.5) | 40 (23.5) | |
| FNA | |||
| PTC | 119 (91.5) | 11 (8.5) | |
| Suspecouic for PTC | 56 (88.9) | 7 (11.1) | |
| Atypia of Undetermined Significance | 36 (59.0) | 25 (41.0) | |
| Benign | 20 (34.5) | 28 (65.5) | <0.001 ** |
| Follicular Neoplasm | 26 (92.9) | 2 (7.1) | |
| Not diagnostic | 5 (50.0) | 5 (50.0) | |
| Tumor size | |||
| <2 cm | 108 (72.5) | 41 (27.5) | 0.608 |
| 2–<4 cm | 99 (75.6) | 32 (24.4) | |
| ≥4 cm | 55 (78.6) | 15 (21.4) | |
| Margin | |||
| Negative | 122 (73.1) | 45 (26.9) | 0.589 |
| Close | 77 (77.0) | 23 (23.0) | |
| Positive | 51 (76.1) | 16 (23.9) | |
| Parameter | B | Std. Error | 95% Wald CI | Hypothesis Test | Exp (B) | 95% CI for Exp (B) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | Wald Chi-Square | df | Sig. | Lower | Upper | ||||
| (Intercept) | 0.398 | 0.0679 | 0.265 | 0.531 | 34.417 | 1 | <0.001 | 1.489 | 1.304 | 1.701 |
| Age category | ||||||||||
| ≥55 years | 0.140 | 0.0719 | −0.001 | 0.281 | 3.791 | 1 | 0.052 | 1.150 | 0.999 | 1.324 |
| <55 years (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| BMI category | ||||||||||
| Morbid obesity | 0.066 | 0.0740 | −0.079 | 0.211 | 0.790 | 1 | 0.374 | 1.068 | 0.924 | 1.235 |
| Obesity | 0.010 | 0.0707 | −0.128 | 0.149 | 0.021 | 1 | 0.885 | 1.010 | 0.880 | 1.160 |
| Overweight | 0.110 | 0.0670 | −0.022 | 0.241 | 2.676 | 1 | 0.102 | 1.116 | 0.978 | 1.273 |
| Within normal (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| Tumor size | ||||||||||
| ≥4 cm | 0.104 | 0.0646 | −0.022 | 0.231 | 2.598 | 1 | 0.107 | 1.110 | 0.978 | 1.259 |
| 2–4 cm | 0.056 | 0.0538 | −0.050 | 0.161 | 1.074 | 1 | 0.300 | 1.057 | 0.952 | 1.175 |
| <2 cm (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| FNA result | ||||||||||
| Not diagnostic | −0.006 | 0.1453 | −0.291 | 0.278 | 0.002 | 1 | 0.965 | 0.994 | 0.747 | 1.321 |
| Benign | −0.341 | 0.0702 | −0.478 | −0.203 | 23.572 | 1 | <0.001 | 0.711 | 0.620 | 0.816 |
| AUS | −0.356 | 0.0698 | −0.492 | −0.219 | 25.966 | 1 | <0.001 | 0.701 | 0.611 | 0.803 |
| Follicular Neoplasm | −0.358 | 0.0924 | −0.539 | −0.177 | 14.980 | 1 | <0.001 | 0.699 | 0.583 | 0.838 |
| Suspecouic for PTC | −0.095 | 0.0690 | −0.230 | 0.040 | 1.897 | 1 | 0.168 | 0.909 | 0.794 | 1.041 |
| PTC (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| (Scale) | 0.195 b | 0.0148 | 0.168 | 0.226 | ||||||
| Parameter | B | Std. Error | 95% Wald CI | Hypothesis Test | Exp (B) | 95% CI for Exp (B) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | Wald Chi-Square | df | Sig. | Lower | Upper | ||||
| (Intercept) | 0.339 | 0.0671 | 0.207 | 0.470 | 25.529 | 1 | <0.001 | 1.403 | 1.231 | 1.601 |
| Age category | ||||||||||
| ≥55 years | 0.241 | 0.0718 | 0.101 | 0.382 | 11.290 | 1 | <0.001 | 1.273 | 1.106 | 1.465 |
| <55 years (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| BMI category | ||||||||||
| Morbid obesity | 0.077 | 0.0732 | −0.066 | 0.221 | 1.107 | 1 | 0.293 | 1.080 | 0.936 | 1.247 |
| Obesity | −0.056 | 0.0698 | −0.193 | 0.081 | 0.640 | 1 | 0.424 | 0.946 | 0.825 | 1.084 |
| Overweight | −0.004 | 0.0665 | −0.134 | 0.127 | 0.003 | 1 | 0.958 | 0.996 | 0.875 | 1.135 |
| Within normal (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| Tumor size | ||||||||||
| ≥4 cm | 0.251 | 0.0644 | 0.125 | 0.378 | 15.221 | 1 | <0.001 | 1.286 | 1.133 | 1.459 |
| 2–4 cm | 0.207 | 0.0533 | 0.103 | 0.312 | 15.071 | 1 | <0.001 | 1.230 | 1.108 | 1.366 |
| <2 cm (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| FNA result | ||||||||||
| Not diagnostic | −0.272 | 0.1496 | −0.565 | 0.022 | 3.297 | 1 | 0.069 | 0.762 | 0.568 | 1.022 |
| Benign | −0.308 | 0.0703 | −0.446 | −0.170 | 19.215 | 1 | <0.001 | 0.735 | 0.640 | 0.843 |
| AUS | −0.273 | 0.0691 | −0.409 | −0.138 | 15.670 | 1 | <0.001 | 0.761 | 0.664 | 0.871 |
| Follicular Neoplasm | −0.303 | 0.0922 | −0.484 | −0.122 | 10.800 | 1 | 0.001 | 0.739 | 0.617 | 0.885 |
| Suspecouic for PTC | −0.148 | 0.0682 | −0.282 | −0.015 | 4.736 | 1 | 0.030 | 0.862 | 0.754 | 0.985 |
| PTC (ref) | 0 a | . | . | . | . | . | . | 1 | . | . |
| (Scale) | 0.187 b | 0.0144 | 0.161 | 0.217 | ||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alaidaroos, O.Z.; Aldhahri, S.F.; Alanazi, T.B.; Alanazi, M.S.; Alqahtani, K.H.; Alessa, M.; Fnais, N.; Alzahrani, F.R. Impact of Surgical Timing on Outcome in Papillary Thyroid Cancer Patients in Saudi Arabia. J. Clin. Med. 2025, 14, 8662. https://doi.org/10.3390/jcm14248662
Alaidaroos OZ, Aldhahri SF, Alanazi TB, Alanazi MS, Alqahtani KH, Alessa M, Fnais N, Alzahrani FR. Impact of Surgical Timing on Outcome in Papillary Thyroid Cancer Patients in Saudi Arabia. Journal of Clinical Medicine. 2025; 14(24):8662. https://doi.org/10.3390/jcm14248662
Chicago/Turabian StyleAlaidaroos, Omar Zaki, Saleh F. Aldhahri, Talal Banan Alanazi, Malak Satam Alanazi, Khalid H. Alqahtani, Mohammed Alessa, Naif Fnais, and Faisal R. Alzahrani. 2025. "Impact of Surgical Timing on Outcome in Papillary Thyroid Cancer Patients in Saudi Arabia" Journal of Clinical Medicine 14, no. 24: 8662. https://doi.org/10.3390/jcm14248662
APA StyleAlaidaroos, O. Z., Aldhahri, S. F., Alanazi, T. B., Alanazi, M. S., Alqahtani, K. H., Alessa, M., Fnais, N., & Alzahrani, F. R. (2025). Impact of Surgical Timing on Outcome in Papillary Thyroid Cancer Patients in Saudi Arabia. Journal of Clinical Medicine, 14(24), 8662. https://doi.org/10.3390/jcm14248662

